Dataset Information

Identifying potential biological processes and key targets in COVID-19-associated heart failure.

ABSTRACT: Novel coronavirus pneumonia (COVID-19) is a new type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has spread rapidly and become a global pandemic. Heart failure (HF) is the ultimate period of the development of various cardiovascular diseases. There are several research have found that SARS-CoV-2 infection may induce cardiac complications including enhanced cardiac stress biomarkers and heart failure. Our research aims at identifying underlying biological processes and key targets in COVID-19-associated heart failure via bioinformatics analysis. A total of three heart failure datasets and three COVID-19 datasets were obtained using the Gene Expression Omnibus (GEO) database. Batch effects cross each sample were eliminated with surrogate variable analysis algorithm. Then, we identified key modules of COVID-19 datasets and heart failure datasets through weighted gene co-expression network analysis. HF-associated as well as COVID-19-associated key modules were intersected for determining the shared genes of COVID-19-associated heart failure. The pivotal genes associated with COVID-19-related heart failure were determined by intersecting the shared genes with the HF-associated hub genes selected through WGCNA. Furthermore, we conducted GO as well as KEGG enrichment analysis on shared genes of COVID-19-associated heart failure. Two COVID-19-associated key modules as well as three HF-associated key modules were determined. In addition, eleven shared genes for COVID-19-associated heart failure were determined. In conclusion, our work screened two critical genes, namely PYGM and BLM, which may be possible intervention targets for COVID-19-associated heart failure. According to functional enrichment results, the shared genes of COVID-19-associated heart failure showed high enrichment in starch and sucrose metabolism, homologous recombination, Fanconi anemia pathway, and insulin resistance indicate the probably biological processes linked to COVID-19-associated heart failure. These results provided further insights in possible interventional and therapeutic targets of COVID-19-associated heart failure.

SUBMITTER: Li J

PROVIDER: S-EPMC10404953 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Identifying potential biological processes and key targets in COVID-19-associated heart failure.

Li Jia J Guo Zhifu Z Song Xiaowei X

Heliyon 20230725 8

Novel coronavirus pneumonia (COVID-19) is a new type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has spread rapidly and become a global pandemic. Heart failure (HF) is the ultimate period of the development of various cardiovascular diseases. There are several research have found that SARS-CoV-2 infection may induce cardiac complications including enhanced cardiac stress biomarkers and heart failure. Our research aims at identifying underlying b ...[more]

PMID: 37554802

Similar Datasets

Project description:Background: Coronavirus (CoV) is an emerging human pathogen causing severe acute respiratory syndrome (SARS) around the world. Earlier identification of biomarkers for SARS can facilitate detection and reduce the mortality rate of the disease. Thus, by integrated network analysis and structural modeling approach, we aimed to explore the potential drug targets and the candidate drugs for coronavirus medicated SARS. Methods: Differentially expression (DE) analysis of CoV infected host genes (HGs) expression profiles was conducted by using the Limma. Highly integrated DE-CoV-HGs were selected to construct the protein-protein interaction (PPI) network. Results: Using the Walktrap algorithm highly interconnected modules include module 1 (202 nodes); module 2 (126 nodes) and module 3 (121 nodes) modules were retrieved from the PPI network. MYC, HDAC9, NCOA3, CEBPB, VEGFA, BCL3, SMAD3, SMURF1, KLHL12, CBL, ERBB4, and CRKL were identified as potential drug targets (PDTs), which are highly expressed in the human respiratory system after CoV infection. Functional terms growth factor receptor binding, c-type lectin receptor signaling, interleukin-1 mediated signaling, TAP dependent antigen processing and presentation of peptide antigen via MHC class I, stimulatory T cell receptor signaling, and innate immune response signaling pathways, signal transduction and cytokine immune signaling pathways were enriched in the modules. Protein-protein docking results demonstrated the strong binding affinity (-314.57 kcal/mol) of the ERBB4-3cLpro complex which was selected as a drug target. In addition, molecular dynamics simulations indicated the structural stability and flexibility of the ERBB4-3cLpro complex. Further, Wortmannin was proposed as a candidate drug to ERBB4 to control SARS-CoV-2 pathogenesis through inhibit receptor tyrosine kinase-dependent macropinocytosis, MAPK signaling, and NF-kb singling pathways that regulate host cell entry, replication, and modulation of the host immune system. Conclusion: We conclude that CoV drug target "ERBB4" and candidate drug "Wortmannin" provide insights on the possible personalized therapeutics for emerging COVID-19.

Project description:Coronavirus disease-19 (COVID-19), caused by SARS-CoV-2, has contributed to a significant increase in mortality. Proinflammatory cytokine-mediated cytokine release syndrome (CRS) contributes significantly to COVID-19. Meliae cortex has been reported for its several ethnomedical applications in the Chinese Pharmacopoeia. In combination with other traditional Chinese medicines (TCM), the Meliae cortex suppresses coronavirus. Due to its phytoconstituents and anti-inflammatory capabilities, we postulated that the Meliae cortex could be a potential therapeutic for treating COVID-19. The active phytonutrients, molecular targets, and pathways of the Meliae cortex have not been explored yet for COVID-19 therapy. We performed network pharmacology analysis to determine the active phytoconstituents, molecular targets, and pathways of the Meliae cortex for COVID-19 treatment. 15 active phytonutrients of the Meliae cortex and 451 their potential gene targets were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and SwissTargetPrediction website tool, respectively. 1745 COVID-19-related gene targets were recovered from the GeneCards. 104 intersection gene targets were determined by performing VENNY analysis. Using the DAVID tool, gene ontology (GO) and KEGG pathway enrichment analysis were performed on the intersection gene targets. Using the Cytoscape software, the PPI and MCODE analyses were carried out on the intersection gene targets, which resulted in 41 potential anti-COVID-19 core targets. Molecular docking was performed with AutoDock Vina. The 10 anti-COVID-19 core targets (AKT1, TNF, HSP90AA1, IL-6, mTOR, EGFR, CASP3, HIF1A, MAPK3, and MAPK1), three molecular pathways (the PI3K-Akt signaling pathway, the HIF-1 signaling pathway, and the pathways in cancer) and three active phytonutrients (4,8-dimethoxy-1-vinyl-beta-carboline, Trichilinin D, and Nimbolin B) were identified as molecular targets, molecular pathways, and key active phytonutrients of the Meliae cortex, respectively that significantly contribute to alleviating COVID-19. Molecular docking analysis further corroborated that three Meliae cortex's key active phytonutrients may ameliorate COVID-19 disease by modulating identified targets. Hence, this research offers a solid theoretic foundation for the future development of anti-COVID-19 therapeutics based on the phytonutrients of the Meliae cortex.

Dataset Information

Identifying potential biological processes and key targets in COVID-19-associated heart failure.

Publications

Identifying potential biological processes and key targets in COVID-19-associated heart failure.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets